Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
Objectives. To correlate the abnormalities on computed tomography, magnetic resonance imaging, and bone scan with fluorinated deoxyglucose positron emission tomography (FDG-PET) in patients with progressive metastatic prostate cancer, using a lesion-by-lesion analysis, and to preliminarily explore p...
Gespeichert in:
| Veröffentlicht in: | Urology (Ridgewood, N.J.) N.J.), 2002-06, Vol.59 (6), p.913-918 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 918 |
|---|---|
| container_issue | 6 |
| container_start_page | 913 |
| container_title | Urology (Ridgewood, N.J.) |
| container_volume | 59 |
| creator | Morris, Michael J Akhurst, Timothy Osman, Iman Nunez, Rodolfo Macapinlac, Homer Siedlecki, Karen Verbel, David Schwartz, Lawrence Larson, Steven M Scher, Howard I |
| description | Objectives. To correlate the abnormalities on computed tomography, magnetic resonance imaging, and bone scan with fluorinated deoxyglucose positron emission tomography (FDG-PET) in patients with progressive metastatic prostate cancer, using a lesion-by-lesion analysis, and to preliminarily explore post-treatment changes in standard uptake value (SUV) with changes in prostate-specific antigen (PSA).
Methods. A lesional analysis compared abnormalities on FDG-PET with those on CT/MRI or bone scan. Patients had rising PSA levels and progressive disease according to the imaging findings. Changes in the SUV were compared with the PSA changes in patients who had serial scans after treatment.
Results. One hundred fifty-seven lesions in 17 patients were examined; 134 osseous lesions were evident on PET and/or bone scan, 95 lesions (71%) were evident on both, 31 (23%) were seen only on bone scan, and 8 (6%) were seen only on PET (adjusted McNemar’s chi-square = 8.32,
P = 0.004). All but one of the lesions seen only on bone scan were “stable” compared with the previous bone scans. All lesions seen only on PET proved to be active disease on subsequent bone scans. Twenty-three soft-tissue lesions were present on CT/MRI or PET, or both; 9 (39%) lesions were evident on both and 14 (61%) were evident only on one imaging modality. In 9 (75%) of 12 cases in which serial PET scans were available, the SUV changed in parallel with the PSA level.
Conclusions. FDG-PET can discriminate active osseous disease from scintigraphically quiescent lesions in patients with progressive metastatic prostate cancer, but it is limited in detecting soft-tissue metastases. Post-treatment changes in the SUV tend to correlate with changes in PSA. |
| doi_str_mv | 10.1016/S0090-4295(02)01509-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71721701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429502015091</els_id><sourcerecordid>71721701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-17541281e2424774884f3e4be75da48c517102b08250804648f93f6d57a4b26f3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhJ4ByAcEhMOP4KyeEKgpIlTgAZ8vrTIJREi92UrH_Hqe7okdOHo2e8bzzMPYc4S0CqnffAFqoBW_la-BvACW0NT5gO5Rc123byods9w-5YE9y_gUASin9mF0ghwYbAzs2XI9rTGF2C3VVR_HPcRhXHzNVh5jDkuJc0RRyDqVY4hSH5A4_j1WY3BDmoQpzdUilSYW4pWqixeXFLcFv7a2iyrvZU3rKHvVuzPTs_F6yH9cfv199rm--fvpy9eGm9k2LS41aCuQGiQsutBbGiL4hsSctOyeMl6gR-B4Ml2BAKGH6tulVJ7UTe6765pK9Ov1b9v9eKS-2pPc0jm6muGarUXPUgAWUJ9CXoDlRbw-pXJWOFsFuhu2dYbvps8DtnWG7zb04L1j3E3X3U2elBXh5Blz2buxTuT_ke65RWgGawr0_cVR03AZKNvtAxVUXEvnFdjH8J8pfR3GY2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71721701</pqid></control><display><type>article</type><title>Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Morris, Michael J ; Akhurst, Timothy ; Osman, Iman ; Nunez, Rodolfo ; Macapinlac, Homer ; Siedlecki, Karen ; Verbel, David ; Schwartz, Lawrence ; Larson, Steven M ; Scher, Howard I</creator><creatorcontrib>Morris, Michael J ; Akhurst, Timothy ; Osman, Iman ; Nunez, Rodolfo ; Macapinlac, Homer ; Siedlecki, Karen ; Verbel, David ; Schwartz, Lawrence ; Larson, Steven M ; Scher, Howard I</creatorcontrib><description>Objectives. To correlate the abnormalities on computed tomography, magnetic resonance imaging, and bone scan with fluorinated deoxyglucose positron emission tomography (FDG-PET) in patients with progressive metastatic prostate cancer, using a lesion-by-lesion analysis, and to preliminarily explore post-treatment changes in standard uptake value (SUV) with changes in prostate-specific antigen (PSA).
Methods. A lesional analysis compared abnormalities on FDG-PET with those on CT/MRI or bone scan. Patients had rising PSA levels and progressive disease according to the imaging findings. Changes in the SUV were compared with the PSA changes in patients who had serial scans after treatment.
Results. One hundred fifty-seven lesions in 17 patients were examined; 134 osseous lesions were evident on PET and/or bone scan, 95 lesions (71%) were evident on both, 31 (23%) were seen only on bone scan, and 8 (6%) were seen only on PET (adjusted McNemar’s chi-square = 8.32,
P = 0.004). All but one of the lesions seen only on bone scan were “stable” compared with the previous bone scans. All lesions seen only on PET proved to be active disease on subsequent bone scans. Twenty-three soft-tissue lesions were present on CT/MRI or PET, or both; 9 (39%) lesions were evident on both and 14 (61%) were evident only on one imaging modality. In 9 (75%) of 12 cases in which serial PET scans were available, the SUV changed in parallel with the PSA level.
Conclusions. FDG-PET can discriminate active osseous disease from scintigraphically quiescent lesions in patients with progressive metastatic prostate cancer, but it is limited in detecting soft-tissue metastases. Post-treatment changes in the SUV tend to correlate with changes in PSA.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/S0090-4295(02)01509-1</identifier><identifier>PMID: 12031380</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Bone Neoplasms - diagnosis ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - secondary ; Fluorodeoxyglucose F18 ; Genital system. Mammary gland ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Radionuclide Imaging ; Radiopharmaceuticals ; Soft Tissue Neoplasms - diagnosis ; Soft Tissue Neoplasms - diagnostic imaging ; Soft Tissue Neoplasms - secondary ; Tomography, X-Ray Computed ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Urology (Ridgewood, N.J.), 2002-06, Vol.59 (6), p.913-918</ispartof><rights>2002 Elsevier Science Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-17541281e2424774884f3e4be75da48c517102b08250804648f93f6d57a4b26f3</citedby><cites>FETCH-LOGICAL-c391t-17541281e2424774884f3e4be75da48c517102b08250804648f93f6d57a4b26f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090429502015091$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13676018$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12031380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Akhurst, Timothy</creatorcontrib><creatorcontrib>Osman, Iman</creatorcontrib><creatorcontrib>Nunez, Rodolfo</creatorcontrib><creatorcontrib>Macapinlac, Homer</creatorcontrib><creatorcontrib>Siedlecki, Karen</creatorcontrib><creatorcontrib>Verbel, David</creatorcontrib><creatorcontrib>Schwartz, Lawrence</creatorcontrib><creatorcontrib>Larson, Steven M</creatorcontrib><creatorcontrib>Scher, Howard I</creatorcontrib><title>Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives. To correlate the abnormalities on computed tomography, magnetic resonance imaging, and bone scan with fluorinated deoxyglucose positron emission tomography (FDG-PET) in patients with progressive metastatic prostate cancer, using a lesion-by-lesion analysis, and to preliminarily explore post-treatment changes in standard uptake value (SUV) with changes in prostate-specific antigen (PSA).
Methods. A lesional analysis compared abnormalities on FDG-PET with those on CT/MRI or bone scan. Patients had rising PSA levels and progressive disease according to the imaging findings. Changes in the SUV were compared with the PSA changes in patients who had serial scans after treatment.
Results. One hundred fifty-seven lesions in 17 patients were examined; 134 osseous lesions were evident on PET and/or bone scan, 95 lesions (71%) were evident on both, 31 (23%) were seen only on bone scan, and 8 (6%) were seen only on PET (adjusted McNemar’s chi-square = 8.32,
P = 0.004). All but one of the lesions seen only on bone scan were “stable” compared with the previous bone scans. All lesions seen only on PET proved to be active disease on subsequent bone scans. Twenty-three soft-tissue lesions were present on CT/MRI or PET, or both; 9 (39%) lesions were evident on both and 14 (61%) were evident only on one imaging modality. In 9 (75%) of 12 cases in which serial PET scans were available, the SUV changed in parallel with the PSA level.
Conclusions. FDG-PET can discriminate active osseous disease from scintigraphically quiescent lesions in patients with progressive metastatic prostate cancer, but it is limited in detecting soft-tissue metastases. Post-treatment changes in the SUV tend to correlate with changes in PSA.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - diagnosis</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - secondary</subject><subject>Fluorodeoxyglucose F18</subject><subject>Genital system. Mammary gland</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><subject>Radionuclide Imaging</subject><subject>Radiopharmaceuticals</subject><subject>Soft Tissue Neoplasms - diagnosis</subject><subject>Soft Tissue Neoplasms - diagnostic imaging</subject><subject>Soft Tissue Neoplasms - secondary</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EokvhJ4ByAcEhMOP4KyeEKgpIlTgAZ8vrTIJREi92UrH_Hqe7okdOHo2e8bzzMPYc4S0CqnffAFqoBW_la-BvACW0NT5gO5Rc123byods9w-5YE9y_gUASin9mF0ghwYbAzs2XI9rTGF2C3VVR_HPcRhXHzNVh5jDkuJc0RRyDqVY4hSH5A4_j1WY3BDmoQpzdUilSYW4pWqixeXFLcFv7a2iyrvZU3rKHvVuzPTs_F6yH9cfv199rm--fvpy9eGm9k2LS41aCuQGiQsutBbGiL4hsSctOyeMl6gR-B4Ml2BAKGH6tulVJ7UTe6765pK9Ov1b9v9eKS-2pPc0jm6muGarUXPUgAWUJ9CXoDlRbw-pXJWOFsFuhu2dYbvps8DtnWG7zb04L1j3E3X3U2elBXh5Blz2buxTuT_ke65RWgGawr0_cVR03AZKNvtAxVUXEvnFdjH8J8pfR3GY2A</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Morris, Michael J</creator><creator>Akhurst, Timothy</creator><creator>Osman, Iman</creator><creator>Nunez, Rodolfo</creator><creator>Macapinlac, Homer</creator><creator>Siedlecki, Karen</creator><creator>Verbel, David</creator><creator>Schwartz, Lawrence</creator><creator>Larson, Steven M</creator><creator>Scher, Howard I</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer</title><author>Morris, Michael J ; Akhurst, Timothy ; Osman, Iman ; Nunez, Rodolfo ; Macapinlac, Homer ; Siedlecki, Karen ; Verbel, David ; Schwartz, Lawrence ; Larson, Steven M ; Scher, Howard I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-17541281e2424774884f3e4be75da48c517102b08250804648f93f6d57a4b26f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - diagnosis</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - secondary</topic><topic>Fluorodeoxyglucose F18</topic><topic>Genital system. Mammary gland</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><topic>Radionuclide Imaging</topic><topic>Radiopharmaceuticals</topic><topic>Soft Tissue Neoplasms - diagnosis</topic><topic>Soft Tissue Neoplasms - diagnostic imaging</topic><topic>Soft Tissue Neoplasms - secondary</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Akhurst, Timothy</creatorcontrib><creatorcontrib>Osman, Iman</creatorcontrib><creatorcontrib>Nunez, Rodolfo</creatorcontrib><creatorcontrib>Macapinlac, Homer</creatorcontrib><creatorcontrib>Siedlecki, Karen</creatorcontrib><creatorcontrib>Verbel, David</creatorcontrib><creatorcontrib>Schwartz, Lawrence</creatorcontrib><creatorcontrib>Larson, Steven M</creatorcontrib><creatorcontrib>Scher, Howard I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morris, Michael J</au><au>Akhurst, Timothy</au><au>Osman, Iman</au><au>Nunez, Rodolfo</au><au>Macapinlac, Homer</au><au>Siedlecki, Karen</au><au>Verbel, David</au><au>Schwartz, Lawrence</au><au>Larson, Steven M</au><au>Scher, Howard I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>59</volume><issue>6</issue><spage>913</spage><epage>918</epage><pages>913-918</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives. To correlate the abnormalities on computed tomography, magnetic resonance imaging, and bone scan with fluorinated deoxyglucose positron emission tomography (FDG-PET) in patients with progressive metastatic prostate cancer, using a lesion-by-lesion analysis, and to preliminarily explore post-treatment changes in standard uptake value (SUV) with changes in prostate-specific antigen (PSA).
Methods. A lesional analysis compared abnormalities on FDG-PET with those on CT/MRI or bone scan. Patients had rising PSA levels and progressive disease according to the imaging findings. Changes in the SUV were compared with the PSA changes in patients who had serial scans after treatment.
Results. One hundred fifty-seven lesions in 17 patients were examined; 134 osseous lesions were evident on PET and/or bone scan, 95 lesions (71%) were evident on both, 31 (23%) were seen only on bone scan, and 8 (6%) were seen only on PET (adjusted McNemar’s chi-square = 8.32,
P = 0.004). All but one of the lesions seen only on bone scan were “stable” compared with the previous bone scans. All lesions seen only on PET proved to be active disease on subsequent bone scans. Twenty-three soft-tissue lesions were present on CT/MRI or PET, or both; 9 (39%) lesions were evident on both and 14 (61%) were evident only on one imaging modality. In 9 (75%) of 12 cases in which serial PET scans were available, the SUV changed in parallel with the PSA level.
Conclusions. FDG-PET can discriminate active osseous disease from scintigraphically quiescent lesions in patients with progressive metastatic prostate cancer, but it is limited in detecting soft-tissue metastases. Post-treatment changes in the SUV tend to correlate with changes in PSA.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12031380</pmid><doi>10.1016/S0090-4295(02)01509-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-4295 |
| ispartof | Urology (Ridgewood, N.J.), 2002-06, Vol.59 (6), p.913-918 |
| issn | 0090-4295 1527-9995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71721701 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Aged, 80 and over Biological and medical sciences Bone Neoplasms - diagnosis Bone Neoplasms - diagnostic imaging Bone Neoplasms - secondary Fluorodeoxyglucose F18 Genital system. Mammary gland Humans Investigative techniques, diagnostic techniques (general aspects) Magnetic Resonance Imaging Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Radiodiagnosis. Nmr imagery. Nmr spectrometry Radionuclide Imaging Radiopharmaceuticals Soft Tissue Neoplasms - diagnosis Soft Tissue Neoplasms - diagnostic imaging Soft Tissue Neoplasms - secondary Tomography, X-Ray Computed Tumors of the urinary system Urinary tract. Prostate gland |
| title | Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T20%3A18%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fluorinated%20deoxyglucose%20positron%20emission%20tomography%20imaging%20in%20progressive%20metastatic%20prostate%20cancer&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Morris,%20Michael%20J&rft.date=2002-06-01&rft.volume=59&rft.issue=6&rft.spage=913&rft.epage=918&rft.pages=913-918&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/S0090-4295(02)01509-1&rft_dat=%3Cproquest_cross%3E71721701%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71721701&rft_id=info:pmid/12031380&rft_els_id=S0090429502015091&rfr_iscdi=true |